SCHEMBL6901517

SCHEMBL6901517

CCc1cc2c(Cl)nc(C3CCC(=CC(=O)OC)CC3)nc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMIGD3 P0DMS9 2/20 0.41
ADORA1 P30542 1/20 0.41
SELE P16581 1/20 0.37
VCAM1 P19320 1/20 0.37
ALDH1A1 P00352 7/20 0.36
ESR2 Q92731 1/20 0.34
KDM4E B2RXH2 5/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HPGD P15428 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PDE10A Q9Y233 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6901515 0.80 TMIGD3 (0.45) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6706615 0.73 NPC1 (0.45) ALDH1A1KDM4EHSD17B10KMT2AHPGD
SCHEMBL1966694 0.70 SELE (0.48) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6706646 0.66 SELE (0.44) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6706662 0.65 SELE (0.42) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL8187273 0.65 PRKCI (0.44) SELEVCAM1ALDH1A1KDM4EHSD17B10
SCHEMBL1970286 0.64 SELE (0.60) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6708399 0.64 SELE (0.41) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL31045293 0.64 PDE10A (0.50) PDE10A
Bicarbonate SCHEMBL7016622 0.63 PDE5A (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077664-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates MERCK PATENT GMBH (DE) 2004-04-22 US disclosed
US-20040072846-A1 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives MERCK PATENT GMBH (DE) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077664-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates PTGIS, DPYD, PTGIR TMIGD3 3660/4885ADORA1 290/4885SELE 4109/4885
US-20040072846-A1 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives PTGER1, TBXA2R, PTGIS TMIGD3 3111/4885ADORA1 270/4885SELE 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.